ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical Response"

  • Abstract Number: 591 • 2018 ACR/ARHP Annual Meeting

    Evaluation of MRI Ramris Score and Clinical Response in Patients with ACPA Positive Undifferentiated Arthritis Treated with Infliximab Versus Placebo

    Thomas Kirchgesner1, Bruno Vande Berg1, Tatiana Sokolova2, Laurent Meric de Bellefon2, Adrien Nzeusseu Toukap3, Maria Stoenoiu4 and Patrick Durez2, 1Musculoskeletal Imaging Unit, Musculoskeletal Imaging Unit - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 2Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 3Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 4Rheumatology department, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium

    Background/Purpose: Patients (Pts) with Undifferentiated Arthritis (UA), positive for ACPA antibodies are at high risk of progressing to Rheumatoid Arthritis (RA). TNF play a key…
  • Abstract Number: 662 • 2018 ACR/ARHP Annual Meeting

    Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab for up to 3 Years

    Désirée van der Heijde1, Vinod Chandran2, Roy Fleischmann3, Olivier Benichou4, Suchitrita Rathmann4 and Catherine Shuler4, 1Leiden University Medical Centre, Leiden, Netherlands, 2Krembil Research Institute & University of Toronto, Toronto, ON, Canada, 3University of Texas Southwestern Medical Center, Dallas, TX, 4Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, was shown to be superior to placebo (PBO) in inhibiting the progression of structural joint damage in patients (pts)…
  • Abstract Number: 686 • 2018 ACR/ARHP Annual Meeting

    Five-Year Efficacy and Safety of Apremilast Treatment in Subjects with Psa: A Pooled Analysis of the 3 Phase III Studies

    Arthur Kavanaugh1, Dafna D Gladman2, Christopher J. Edwards3, Georg Schett4, Benoit Guerette5, Nikolay Delev5, Lichen Teng5, Maria Paris5 and Philip J. Mease6, 1University of California, San Diego, School of Medicine, La Jolla, CA, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3University of Southampton, Southampton, United Kingdom, 4Friedrich-Alexander-Universität Erlangen, Nürnberg und Universitätsklinikum Erlangen, Erlangen, Germany, 5Celgene Corporation, Summit, NJ, 6Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Long-term apremilast (APR) efficacy and safety were evaluated for up to 5 yrs in adults with active PsA in the phase III PALACE 1-3…
  • Abstract Number: 1408 • 2018 ACR/ARHP Annual Meeting

    Using Patient Reported Outcomes at Point of Care in Immune Mediated Diseases: Minimal Clinically Important Differences

    M. Elaine Husni1, Chad Deal2, Leonard H. Calabrese3, Greg Strnad4, James Bena5 and Abby Abelson6, 1Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Shaker Heights, OH, 3Rheumatology, Cleveland Clinic, Cleveland, OH, 4Cleveland Clinic, Cleveland, OH, 5Quantitative Health Science, QHS Cleveland Clinic, Cleveland, OH, 6Department of Rheumatologic & Immunologic Disease, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Patient reported measures of global health and disease activity are increasingly used in routine care; however, detecting meaningful change in clinical status (responsiveness) is difficult…
  • Abstract Number: 1544 • 2018 ACR/ARHP Annual Meeting

    Tofacitinib Safety and Efficacy in the Treatment of Rheumatoid Arthritis in a Central/Eastern European Subpopulation

    Jiri Vencovsky1, Janusz Badurski2, Šárka Forejtová1, Olga Lukáčová3, Mykola Stanislavchuk4, Daniela Yaneva-Bichovska5, Harry Shi6, Radu Vasilescu7, Tatjana Lukic8 and Martin Kabina9, 1Institute of Rheumatology, Prague, Czech Republic, 2Centre of Osteoporosis and Osteoarticular Diseases, Bialystok, Poland, 3National Institute for Rheumatic Diseases, Piešťany, Slovakia, 4Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine, 5Medical Centre Synexus, Sofia, Bulgaria, 6Pfizer Inc, Collegeville, PA, 7Pfizer Regional Medical Europe, Brussels, Belgium, 8Pfizer Inc, New York, NY, 9Pfizer Innovative Health, Prague, Czech Republic

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post hoc analysis assessed tofacitinib safety and efficacy in the Central…
  • Abstract Number: 2285 • 2018 ACR/ARHP Annual Meeting

    Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis

    Takayuki Kishi1,2, William Warren-Hicks3, Nastaran Bayat1, Ira Targoff4, Terri H Finkel5, Ellen Goldmuntz6, Michael Henrickson7, Bianca Lang8, Andrew Mammen9, Lauren M. Pachman10, Murray Passo11, Terrance P. O'Hanlon1, Frederick W. Miller1, Michael Ward9 and Lisa G. Rider1, 1Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 2Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, 3EcoStat, Inc., Mebane, NC, 4VA Medical Center, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Department of Pediatrics, Nemours Children's Health System/ Nemours Children's Hospital, Orlando, FL, 6NIAID, NIH, Bethesda, MD, 7Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, NS, Canada, 9National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 10Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 11Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC

    Background/Purpose: We examined patients in a large juvenile dermatomyositis (JDM) registry for frequency of and factors associated with final corticosteroid discontinuation (Steroid DC), complete clinical…
  • Abstract Number: 2464 • 2018 ACR/ARHP Annual Meeting

    Clinimetric and Drug Use Differences in Colombian Patients with Early and Established Rheumatoid Arthritis

    Jorge Florez-Suarez1, Paul Mendez2, Edna Bermudez1, Paola Coral2 and Gerardo Quintana-Lopez1,3, 1Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogotá, Colombia, 2Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogota, Colombia, 3School of medicine, Universidad Nacional de Colombia, Bogotá, Colombia

    Background/Purpose: Current guidelines for RA treatment are focused on the importance of defining the duration of symptoms before diagnosis to achieve better outcomes. This concept…
  • Abstract Number: 2504 • 2018 ACR/ARHP Annual Meeting

    A More Time Under Remission Impacts in a Better Health-Related Quality of Life in Rheumatoid Arthritis Mestizo Population

    Rocío Gamboa-Cárdenas1, Manuel Ugarte-Gil2,3, Mariela Medina-Chinchon1, Cristina Reategui-Sokolova1, Francisco Zevallos1, Victor R. Pimentel-Quiroz1, Claudia Elera-Fitzcarrald1,4, Jose Alfaro-Lozano1, Zoila Rodriguez-Bellido1,5, Risto Perich-Campos1,5 and Cesar A. Pastor-Asurza1,5, 1Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 2Rheumatology, Universidad Científica del Sur, Lima, Peru, 3Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 4Universidad Científica del Sur, Lima, Peru, 5Universidad Nacional Mayor de San Marcos, Lima, Peru

    Background/Purpose: In Rheumatoid Arthritis (RA), sustained remission is associated with less disability (1,2) , and this outcome should be the goal in the RA treatment;…
  • Abstract Number: 2546 • 2018 ACR/ARHP Annual Meeting

    The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib

    Vibeke Strand1, Nemanja Damjanov2, Craig Scoville3, Namita Tundia4, Heidi S. Camp4, Kun Chen4, Jessica Suboticki4 and Ronald van Vollenhoven5, 1Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, 3Idaho Falls Arthritis Clinic, Idaho Falls, ID, 4AbbVie Inc., North Chicago, IL, 5Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands

    Background/Purpose: Patient-reported outcomes (PROs) in RA are important to evaluate total disease impact, although treatment decisions may often be guided by traditional physician-derived measures of…
  • Abstract Number: 1518 • 2017 ACR/ARHP Annual Meeting

    Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data

    Arantxa Conesa1, Manuel Fernández2, Rosa Expósito3, Jose Campos4, Jose Ramon Lamua5, Maria del Pilar Navarro6, Paula Rubio-Muñoz7, Pilar Ahijado-Guzman8 and Carlos M Gonzalez9, 1Hospital Clínico Universitario de Valencia, Valencia, Spain, 2Hospital Universitario de Guadalajara, Guadalajara, Spain, 3Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, 4Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 5Hospital del Henares, Madrid, Spain, 6Hospital de Fuenlabrada, Fuenlabrada, Spain, 7Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 8Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, 9Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: To evaluate the effectiveness and safety of Certolizumab Pegol (CZP) in a real word setting in Psoriatic Arthritis (PsA) patients. Methods: Multicentric cohort of…
  • Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting

    Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials

    Mimi Kim1, Joan T. Merrill2, Kenneth C. Kalunian3, Leslie Hanrahan4 and Peter M. Izmirly5, 1Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, 4Lupus Foundation of America, Washington DC, DC, 5Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…
  • Abstract Number: 2371 • 2017 ACR/ARHP Annual Meeting

    The Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis Stratified By Baseline Body Mass Index

    Ara Dikranian1, Miguel Angel Gonzalez-Gay2, Frank Wellborne3, Jose Maria Alvaro-Gracia4, Liza Takiya5, Lori Stockert5, Douglass Chapman6, Svitlana Tatulych7, Palle Dahl8 and Jeffrey R. Curtis9, 1Cabrillo Center for Rheumatic Disease, San Diego, CA, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Houston Institute for Clinical Research, Houston, TX, 4Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, 5Pfizer Inc, Collegeville, PA, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Ballerup, Denmark, 9University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post-hoc analysis aims to explore the efficacy of tofacitinib…
  • Abstract Number: 2454 • 2017 ACR/ARHP Annual Meeting

    Real-World Consistency of Response to Adalimumab over Time in Patients with Rheumatoid Arthritis: Results from the Corrona Registry

    Dimitrios A. Pappas1,2, George W. Reed2,3, Chitra Karki4, Jenny Griffith5, Martha Skup5, Vishvas Garg5 and Joel Kremer2,6, 1Columbia University, New York, NY, 2Corrona LLC, Southborough, MA, 3UMass Medical School, Worcester, MA, 4Corrona, LLC, Southborough, MA, 5AbbVie Inc., North Chicago, IL, 6Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Adalimumab (ADA) was approved in the US in 2002 for rheumatoid arthritis (RA), and subsequently approved for the management of other inflammatory diseases such…
  • Abstract Number: 2487 • 2017 ACR/ARHP Annual Meeting

    Comparison the Long-Term Clinical Outcomes between Non Anti-TNF Versus Anti-TNF in RA Patients Who Failed to a First Anti-TNF

    Patricia Bogas1, Chamaida Plasencia-Rodriguez1, Alejandro Balsa1, Victoria Navarro-Compán2, Gema Bonilla1, Enrique Moral Coro1, Carolina Tornero1, Laura Nuño1 and Diana Peiteado3, 1Hospital Universitario La Paz, Madrid, Spain, 2Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 3Rheumatology, La Paz University Hospital, Madrid, Spain

    Background/Purpose: There are many biological therapies for Rheumatoid Arthritis (RA) with different mechanisms of action and good efficacy rate; however, up to 40% of patients…
  • Abstract Number: 2602 • 2017 ACR/ARHP Annual Meeting

    Identification of Clinical and Serological Predictive Factors of Response to Rituximab Treatment in Systemic LUPUS Erythematosus (SLE) Patients

    Hiurma Sanchez-Perez1 and David A. Isenberg2, 1Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 2Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Response to Rituximab (RTX) varies significantly between Systemic Lupus Erythematosus (SLE) patients. Ethnicity may play a role in these differences, and a possible relationship…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology